‘Text/HTML’ of page ‘NRG-GU011: Limited Metastatic “Oligometastatic” Prostate Cancer’
Frequently Asked Questions Below, you can find FAQs about clinical research and this particular clinical trial.
Read MoreContent Block Tag: NRG-GU011: Limited Metastatic "Oligometastatic" Prostate Cancer
‘Text/HTML’ of page ‘NRG-GU011: Limited Metastatic “Oligometastatic” Prostate Cancer’
Am I eligible for this study? If you are over the age of 18 with advanced-stage prostate cancer that has returned and spread with a limited number of metastases (up to 5 lesions) following treatment and you are NOT currently receiving androgen deprivation therapy, you may be able to participate. Your healthcare team is the […]
Read More‘Text/HTML’ of page ‘NRG-GU011: Limited Metastatic “Oligometastatic” Prostate Cancer’
About This Study NRG-GU011, also known as the “NRG PROMETHEAN” study, is a study for men who were treated with either surgery or radiation for prostate cancer, and whose cancer has returned and is visible on a PET scan. If there are 5 or fewer lesions, known as oligometastatic disease, men would be eligible […]
Read More‘Text/HTML’ of page ‘NRG-GU011: Limited Metastatic “Oligometastatic” Prostate Cancer’
Clinical Studies FAQ
Read More‘Text/HTML’ of page ‘NRG-GU011: Limited Metastatic “Oligometastatic” Prostate Cancer’
The NRG PROMETHEAN Study FAQ
Read More